Is Elanco Animal Health (ELAN) Still Attractive After A 123% One Year Share Price Jump

Simply Wall St.

4 hours ago

If you are looking at Elanco Animal Health and wondering whether the recent run has already priced in the opportunity, this article will help you frame what the current share price could mean for long...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2614741818"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2614741818\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2614741818?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299","is_english":true,"pubTime":"2026-02-25 01:24","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2614741818","market":"hk","top_or_hot":-1,"title":"Is Elanco Animal Health (ELAN) Still Attractive After A 123% One Year Share Price Jump","media":"Simply Wall St.","content":"<div>\n<p>If you are looking at Elanco Animal Health and wondering whether the recent run has already priced in the opportunity, this article will help you frame what the current share price could mean for long...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/is-elanco-animal-health-elan-still-attractive-after-a-123-on\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is Elanco Animal Health (ELAN) Still Attractive After A 123% One Year Share Price Jump</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs Elanco Animal Health (ELAN) Still Attractive After A 123% One Year Share Price Jump\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-02-25 01:24 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/is-elanco-animal-health-elan-still-attractive-after-a-123-on><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are looking at Elanco Animal Health and wondering whether the recent run has already priced in the opportunity, this article will help you frame what the current share price could mean for long...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/is-elanco-animal-health-elan-still-attractive-after-a-123-on\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4561","symbol_name":"索罗斯持仓","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/is-elanco-animal-health-elan-still-attractive-after-a-123-on","article_id":"2614741818","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6121000-choice2-main-header/1585186699299"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nyse-elan/elanco-animal-health/news/is-elanco-animal-health-elan-still-attractive-after-a-123-on","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2614741818","pubTimestamp":1771953846,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are looking at Elanco Animal Health and wondering whether the recent run has already priced in the opportunity, this article will help you frame what the current share price could mean for long term value.\nThe stock finished the last session at US$24.75, with a 1.5% decline over the past week, a 1.4% gain over the past month, a 9.9% gain year to date, and a 122.8% gain over the past year. The 3 year return sits at 113.5% and the 5 year return at a 26.4% decline.\nThese moves have come...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4561":"索罗斯持仓","LU1941712264.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"A\" (USD) INC","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","LU1941712348.USD":"ALLIANZ PET AND ANIMAL WELLBEING \"AT\" (USD) ACC","BK4007":"制药","ELAN":"Elanco Animal Health Inc"},"translate_title":"Elanco Animal Health(ELAN)股价一年上涨123%后仍有吸引力吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"DCF":1,"ELAN":1.5},"content_text":"If you are looking at Elanco Animal Health and wondering whether the recent run has already priced in the opportunity, this article will help you frame what the current share price could mean for long term value. The stock finished the last session at US$24.75, with a 1.5% decline over the past week, a 1.4% gain over the past month, a 9.9% gain year to date, and a 122.8% gain over the past year. The 3 year return sits at 113.5% and the 5 year return at a 26.4% decline. These moves have come alongside ongoing investor interest in the animal health space, where company specific developments and broader sector sentiment can have a strong influence on valuations over multi year periods. For Elanco, this context is important for assessing whether current pricing reflects business fundamentals or more short term optimism or caution. On Simply Wall St's valuation checks, Elanco scores a 5 out of 6 for potential undervaluation. This sets up a closer look at how different valuation approaches frame the stock today and points to an even more complete way of thinking about value that we will come back to at the end.  Elanco Animal Health delivered 122.8% returns over the last year. See how this stacks up to the rest of the Pharmaceuticals industry. AdvertisementApproach 1: Elanco Animal Health Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model projects a company’s future cash flows and then discounts them back to today’s dollars, aiming to estimate what the business might be worth right now based on those projected cash flows. For Elanco Animal Health, the model used is a 2 Stage Free Cash Flow to Equity approach built on cash flow projections. The latest twelve month Free Cash Flow sits at about $420.9 million. Analyst estimates feed into the early years, then Simply Wall St extrapolates further out, with projected Free Cash Flow for 2030 of $711 million. Over the 2026 to 2035 period, the model uses a series of annual Free Cash Flow figures, all in the hundreds of millions of dollars, and discounts each year back to today. On this basis, the DCF output suggests an estimated intrinsic value of about $35.81 per share. Compared with the recent share price of $24.75, that implies roughly a 30.9% discount, which indicates that Elanco is trading below this cash flow based estimate of value. Result: UNDERVALUED Our Discounted Cash Flow (DCF) analysis suggests Elanco Animal Health is undervalued by 30.9%. Track this in your watchlist or portfolio, or discover 56 more high quality undervalued stocks. ELAN Discounted Cash Flow as at Feb 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Elanco Animal Health. Approach 2: Elanco Animal Health Price vs Sales For companies where earnings can be less consistent, the P/S ratio is often a useful cross check because it compares the value of the equity to the revenue being generated, which tends to be more stable than profit in many cases. What investors are really paying for in a P/S multiple is a mix of growth expectations and perceived risk, with higher growth and lower risk often associated with higher “normal” or “fair” multiples, and the reverse typically linked to lower ones. Elanco’s current P/S sits at 2.68x. That is below both the Pharmaceuticals industry average of 4.26x and the peer average of 3.39x. Simply Wall St also provides a “Fair Ratio” of 4.38x, which is the P/S level suggested by its own model, taking into account factors such as Elanco’s earnings growth profile, profit margins, industry, market cap and risk indicators. This Fair Ratio is more tailored than a simple comparison to peers or industry because it adjusts for company specific fundamentals rather than assuming that all businesses in the group deserve similar pricing. Compared with the Fair Ratio of 4.38x, Elanco’s actual P/S of 2.68x indicates that the shares are trading at a discount on this metric. Result: UNDERVALUED NYSE:ELAN P/S Ratio as at Feb 2026 P/S ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 22 top founder-led companies. Upgrade Your Decision Making: Choose your Elanco Animal Health Narrative Earlier we mentioned that there is an even better way to understand valuation. On Simply Wall St's Community page you can use Narratives, where you write your own story for Elanco Animal Health by linking assumptions about future revenue, earnings and margins to a forecast and fair value. You can then compare that fair value to the current price to help decide whether to buy, hold or sell. The platform updates your Narrative automatically as new earnings or news arrive. One investor might plug in a very optimistic Elanco view with a fair value around US$35.81, while another might lean toward a more cautious fair value near US$14.39. You can see those different views side by side and decide which story you think makes the most sense. For Elanco Animal Health, here are previews of two leading Elanco Animal Health Narratives: 🐂 Elanco Animal Health Bull Case Fair value: US$35.81 Implied undervaluation vs last close: about 30.9% Revenue growth assumption: 15.02%  Focuses on Elanco’s shift toward its higher growth Innovation pillar, with Zenrelia and Credelio Quattro presented as key products in pet health. Highlights improving balance sheet metrics, with margin expansion and deleveraging as central themes in the thesis. Uses a multi stage DCF to arrive at a US$35.81 fair value and views the gap to the current US$24.75 share price as a margin of safety tied to execution on the new product cycle.  🐻 Elanco Animal Health Bear Case Fair value: US$20.20 Implied overvaluation vs last close: about 22.5% Revenue growth assumption: 5.20%  Describes heavier R&D and marketing spend, patent expiries, generics and higher compliance costs as potential drags on margins and earnings stability. Points to a sizeable debt load and customer concentration effects as constraints on flexibility and as sources of risk if growth or pricing fall short. Connects these assumptions to a fair value of about US$20.20, close to more cautious analyst targets, and invites you to test whether those revenue, margin and P/E expectations match your own view of the business.  These are two ends of the current range of thinking on Elanco. If you want to see how other investors are connecting the dots between assumptions, forecasts and price, Curious how numbers become stories that shape markets? Explore Community Narratives. Do you think there's more to the story for Elanco Animal Health? Head over to our Community to see what others are saying! NYSE:ELAN 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Elanco Animal Health might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}